InfuSystem Holdings, Inc
INFU NYSE· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$13.94
KIRA · Stoqly’s AI analyst, in plain words
- InfuSystem Holdings, Inc had $143M of revenue in fiscal 2025, up 6.4% on the year before. Over five years, revenue changed +8.1% a year on average.
- Its operating margin was 8.3%, up 3.2 pts: of every 100 in sales, about 8 is left after running the business.
- InfuSystem Holdings, Inc made $6.6M of net profit in fiscal 2025.
- Free cash flow was $23.8M in fiscal 2025, 16.6% of revenue.
- InfuSystem Holdings, Inc returned $9.9M to shareholders in fiscal 2025, 41% of free cash flow. The diluted share count fell 2.8%.
- InfuSystem Holdings, Inc owes $16.4M more than it holds in cash, about 0.7 years of operating profit.
Market cap
$292M
P/E
34.9x
Revenue
$143M
Net income
$6.6M
Free cash flow
$23.8M
Operating margin
8.3%
InfuSystem Holdings, Inc in 30 seconds · fiscal 2025
Are sales growing?
+6.4%
Yes. Sales grew 6.4% last year.
Does it make a profit?
4.6%
A little. It keeps 4.6% of every sale as profit.
Does profit turn into cash?
16.6%
Yes. 16.6% of sales ends up as free cash.
Is debt under control?
0.7x
Yes. It could repay its debt with 0.7 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
34.9x
One share costs 34.9 times its yearly profit per share.
What InfuSystem Holdings, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- InfuSystem Holdings, Inc
- CIK
- 0001337013
InfuSystem Holdings, Inc · INFU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $102M | $110M | $126M | $135M | $143M |
| Revenue growth | 5.1% | 7.4% | 14.4% | 7.2% | 6.4% |
| Gross margin | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% |
| Operating margin | 2.8% | 1.5% | 3.3% | 5.1% | 8.3% |
| Net income | $1.4M | $0.0M | $0.9M | $2.3M | $6.6M |
| Net margin | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% |
| Diluted EPS | $0.06 | $0.00 | $0.04 | $0.11 | $0.31 |
| Cash | |||||
| Cash from operations | $18.3M | $17.5M | $11.2M | $20.5M | $24.4M |
| Capital expenditure | $1.0M | $1.0M | $1.0M | $1.1M | $0.6M |
| Free cash flow | $17.3M | $16.5M | $10.2M | $19.4M | $23.8M |
| FCF margin | 16.9% | 15.0% | 8.1% | 14.4% | 16.6% |
| Share buybacks | $0.6M | $5.5M | $0.2M | $1.2M | $9.9M |
| Share count change | 1.5% | −2.3% | 0.5% | 0.3% | −2.8% |
| Debt and strength | |||||
| Cash and short-term investments | $0.2M | $0.2M | $0.2M | $0.5M | $3.2M |
| Debt incl. finance leases | $33.1M | $33.2M | $29.1M | $23.9M | $19.6M |
| Shareholders' equity | $48.3M | $48.0M | $52.3M | $57.5M | $57.3M |
| Net debt / EBITDA | 1.9x | 2.2x | 1.7x | 1.2x | 0.7x |
| Current ratio | 1.7x | 1.7x | 1.9x | 1.8x | 1.8x |
| Interest coverage | 2.0x | 1.2x | 1.9x | 3.9x | 9.2x |
| Returns and quality | |||||
| Return on capital | 3.5% | 1.3% | 3.3% | 5.5% | 10.5% |
| Return on equity | 3.2% | 0.0% | 1.7% | 4.3% | 11.5% |
| Return on tangible equity | 4.2% | 0.1% | 2.1% | 5.0% | 14.2% |
| Piotroski F-score | 6 | 7 | 7 | 7 | 8 |
| Altman Z'' | 0.0 | −0.2 | 0.4 | 0.9 | 1.3 |
Insiders bought, 12 months
$0.2M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
InfuSystem Holdings, Inc · INFU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.94 a share, the company is worth $292M: 34.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001337013). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.